Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a ...
Forbes

Revive Therapeutics: The Psychedelics Company Working On A Covid-19 Treatment

Forbes contributors publish independent expert analyses and insights. Amanda Siebert is a reporter covering cannabis and psychedelic drugs. Dec 16, 2020, 07:00am EST This article is more than 5 years ...
Nasdaq

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and ...
Nasdaq

Revive Therapeutics and Herman Holdings Enter Into Non-Binding Letter of Intent to Merge

TORONTO, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive") (CSE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research, development, and commercialization of ...
Benzinga.com

Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders

Life sciences company Revive Therapeutics Ltd. RVVTF raised funds to treat infectious diseases and rare disorders, including meth addiction. The company closed a private placement deal — with the ...